$5.96
5.85% yesterday
Nasdaq, May 20, 10:05 pm CET
ISIN
US30068X1037
Symbol
XGN

Exagen Inc Stock price

$5.96
+1.53 34.54% 1M
+1.76 41.90% 6M
+1.86 45.37% YTD
+4.09 218.72% 1Y
+1.18 24.69% 3Y
-7.42 55.46% 5Y
-12.62 67.92% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.37 5.85%
ISIN
US30068X1037
Symbol
XGN
Sector

Key metrics

Market capitalization $130.26m
Enterprise Value $142.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.51
P/S ratio (TTM) P/S ratio 2.30
P/B ratio (TTM) P/B ratio 16.71
Revenue growth (TTM) Revenue growth 1.78%
Revenue (TTM) Revenue $56.72m
EBIT (operating result TTM) EBIT $-14.00m
Free Cash Flow (TTM) Free Cash Flow $-15.45m
Cash position $11.19m
EPS (TTM) EPS $-0.84
P/E forward negative
P/S forward 1.99
EV/Sales forward 2.18
Short interest 0.65%
Show more

Is Exagen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Exagen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

Buy
83%
Hold
17%

Financial data from Exagen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
57 57
2% 2%
100%
- Direct Costs 23 23
0% 0%
41%
34 34
3% 3%
59%
- Selling and Administrative Expenses 40 40
8% 8%
71%
- Research and Development Expense 5.60 5.60
17% 17%
10%
-12 -12
22% 22%
-22%
- Depreciation and Amortization 1.71 1.71
26% 26%
3%
EBIT (Operating Income) EBIT -14 -14
23% 23%
-25%
Net Profit -16 -16
20% 20%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Exagen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exagen Inc Stock News

Neutral
GlobeNewsWire
11 days ago
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its pr...
Neutral
GlobeNewsWire
13 days ago
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.
Neutral
GlobeNewsWire
13 days ago
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock.
More Exagen Inc News

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Head office United States
CEO John Aballi
Employees 209
Founded 2002
Website www.exagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today